申请人:——
公开号:US20040147535A1
公开(公告)日:2004-07-29
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the compounds are described. The compounds according to the invention can be used as or in the case of tumor or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such as, e.g., stent-induced restenosis, endometriosis, Crohn's disease, Hodgkin's disease, leukemia; arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma; eye diseases, such as diabetic retinopathy, neovascular glaucoma; renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy; fibrotic diseases, such as cirrhosis of the liver, mesangial cell proliferative diseases, arteriosclerosis, injuries to nerve tissue, and inhibition of the reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical devices are used to keep vessels open, such as, e.g., stents, as immunosuppressive agents, as a support in scar-free healing, senile keratosis and contact dermatitis. The compounds according to the invention can also be used as VEGFR-
3
inhibitors in the case of lymphangiogenesis.
本发明涉及VEGFR-2和VEGFR-3抑制剂的芴酰胺吡啶酰胺,以及它们的制备和用作治疗由持续血管生成引起的疾病的药物。本发明的化合物可用于或在肿瘤或转移性生长、银屑病、卡波西肉瘤、再狭窄(例如支架引起的再狭窄)、子宫内膜异位症、克罗恩病、霍奇金病、白血病、关节炎(例如类风湿性关节炎)、血管瘤、血管纤维瘤、眼部疾病(例如糖尿病视网膜病变、新生血管性青光眼)、肾脏疾病(例如肾小球肾炎、糖尿病肾病、恶性肾硬化、血栓性微血管病综合征、移植排斥和肾小球病)、纤维化疾病(例如肝硬化、系膜细胞增生性疾病、动脉硬化、神经组织损伤以及在血管假体、机械设备(例如支架)用于保持血管开放后的再闭塞抑制中使用,以及作为免疫抑制剂、无疤愈合的支持、老年角化病和接触性皮炎。本发明的化合物还可用作淋巴生成的VEGFR-3抑制剂。